A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.
Epistemonikos ID: 25cb3ed23994a90a7cf68052ccbabbde83edd970
First added on: Jul 12, 2025